Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation [PDF]
, 2017 RXRA regulates transcription as part of a heterodimer with 14 other nuclear receptors, including the peroxisome proliferator-activated receptors (PPARs).
Arora, Vivek K +7 more
core +2 more sources
Combined proteome and transcriptome analyses for the discovery of urinary biomarkers for urothelial carcinoma [PDF]
, 2013 Background: Proteomic discovery of cancer biomarkers in body fluids is challenging because of their low abundance in a complex background. Altered gene expression in tumours may not reflect protein levels in body fluids.
A Martin +54 more
core +7 more sources
Measurements of complement factor H-related protein (BTA-TRAK (TM) assay) and nuclear matrix protein (NMP22 assay) - Useful diagnostic tools in the diagnosis of urinary bladder cancer? [PDF]
, 2003 Between 1997 and 2000 we investigated in a prospective study the voided urine samples of all consecutive patients undergoing cystoscopy independent from their clinical background (n=705) with the BTA-TRAK(TM) assay (Bard Diagnostics, Redmont, USA ...
Hofmann, Karin +8 more
core +1 more source
Is the bladder filling protocol for prostate cancer patients undergoing radiotherapy fit for purpose? (Abstract only) [PDF]
, 2020 Introduction: Conventional radiotherapy has been planned with a full bladder based on the rationale that it will move the small bowel out of the treatment field and result in greater sparing of the bladder itself[1].
Burns, Donna +2 more
core +1 more source
The Landscape of Long Non-Coding RNA Dysregulation and Clinical Relevance in Muscle Invasive Bladder Urothelial Carcinoma. [PDF]
, 2019 Bladder cancer is one of the most common cancers in the United States, but few advancements in treatment options have occurred in the past few decades.
Chang, Eric Y +7 more
core +1 more source
Intrinsic subtypes and bladder cancer metastasis
Asian Journal of Urology, 2016 Recent studies demonstrated that bladder cancers can be grouped into basal and luminal molecular subtypes that possess distinct biological and clinical characteristics.
David J. McConkey +3 more
doaj +1 more source
Overview of bladder heating technology: matching capabilities with clinical requirements. [PDF]
, 2016 Moderate temperature hyperthermia (40-45°C for 1 h) is emerging as an effective treatment to enhance best available chemotherapy strategies for bladder cancer.
Stauffer, Paul R., van Rhoon, Gerard C.
core +3 more sources
Multifunctional targeting micelle nanocarriers with both imaging and therapeutic potential for bladder cancer. [PDF]
, 2012 BackgroundWe previously developed a bladder cancer-specific ligand (PLZ4) that can specifically bind to both human and dog bladder cancer cells in vitro and in vivo. We have also developed a micelle nanocarrier drug-delivery system.
de Vere White, Ralph +8 more
core +2 more sources
Circulating Tumor Cells Identify Patients with Super-High-Risk Non-Muscle-Invasive Bladder Cancer: Updated Outcome Analysis of a Prospective Single-Center Trial [PDF]
, 2019 Clinical behavior of non-muscle-invasive bladder cancer (NMIBC) is largely unpredictable, and even patients treated according to European Association of Urology recommendations have a heterogeneous prognosis.
Busetto, Gian Maria +9 more
core +1 more source
SnapShot: Bladder Cancer [PDF]
Cancer Cell, 2018 Bladder cancers, the majority of which are urothelial carcinoma, are the most common urinary tract cancers. There are two major disease types, muscle-invasive and non-muscle-invasive, with distinct pathogenesis pathways, molecular features, and clinical outcomes.
Hurst, C, Rosenberg, J, Knowles, M
openaire +2 more sources